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OBJECTIVE—Heterozygous activating mutations of glucoki-
nase have been reported to cause hypoglycemia attributable to
hyperinsulinism in a limited number of families. We report three
children with de novo glucokinase hyperinsulinism mutations
who displayed a spectrum of clinical phenotypes corresponding
to marked differences in enzyme kinetics.
RESEARCH DESIGN AND METHODS—Mutations were di-
rectly sequenced, and mutants were expressed as glutathionyl
S-transferase–glucokinase fusion proteins. Kinetic analysis of
the enzymes included determinations of stability, activity index,
the response to glucokinase activator drug, and the effect of
glucokinase regulatory protein.
RESULTS—Child 1 had an ins454A mutation, child 2 a W99L
mutation, and child 3 an M197I mutation. Diazoxide treatment
was effective in child 3 but ineffective in child 1 and only partially
effective in child 2. Expression of the mutant glucokinase
ins454A, W99L, and M197I enzymes revealed a continuum of high
relative activity indexes in the three children (26, 8.9, and 3.1,
respectively; wild type  1.0). Allosteric responses to inhibition
by glucokinase regulatory protein and activation by the drug
RO0281675 were impaired by the ins454A but unaffected by the
M197I mutation. Estimated thresholds for glucose-stimulated
insulin release were more severely reduced by the ins454A than
the M197I mutation and intermediate in the W99L mutation (1.1,
3.5, and 2.2 mmol/l, respectively; wild type  5.0 mmol/l).
CONCLUSIONS—These results conﬁrm the potency of glucoki-
nase as the pancreatic -cell glucose sensor, and they demon-
strate that responsiveness to diazoxide varies with genotype in
glucokinase hyperinsulinism resulting in hypoglycemia, which
can be more difﬁcult to control than previously believed.
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H
ypoglycemia in infants with congenital hyper-
insulinism has been associated with mutations
that affect the regulation of insulin secretion by
all three major classes of metabolic fuels: glu-
cose, amino acids, and fatty acids (1–6). The most com-
mon of these disorders is caused by recessive mutations of
the -cell ATP-sensitive K
 (KATP) channel; these muta-
tions cause severe neonatal hypoglycemia that does not
respond to medical therapy with diazoxide, a KATP channel
agonist, and often requires near-total pancreatectomy
(7,8). Other genetic forms of congenital hyperinsulinism,
such as dominant mutations of glutamate dehydrogenase,
cause less severe disease, with hypoglycemia that may not
be recognized until childhood or even adult life and that
responds well to diazoxide therapy (4,9–11). In 1998, the
ﬁrst case of hyperinsulinism caused by a dominant gain-
of-function mutation of glucokinase was reported (12).
This remains one of the rarest forms of hyperinsulinism,
and information on its clinical and biochemical manifes-
tations is limited because only a few cases have been
reported subsequently (13–19). Most of these cases have
been identiﬁed because of family histories of hypoglyce-
mia with dominant patterns of transmission, and most
affected individuals were reported to have relatively mild
disease that could be managed medically with diazoxide.
Glucokinase catalyzes the ﬁrst step in glucose metabo-
lism in pancreatic -cells and liver (20). It exists as a
monomer in three conformations that control catalytic
function: a closed form, an open form, and a super open
form (21). Transitions between these conformations are
controlled by glucose concentration, giving a sigmoidal
enzyme activity curve, as well as by allosteric modulators.
Binding of novel glucokinase activator molecules, such as
RO0281675, to the allosteric site increases glucokinase
activity, resulting in both augmented hepatic glucose up-
take and lowering of the -cell threshold for glucose-
stimulated insulin release (22). In the liver, glucokinase
enzyme activity is inhibited by binding of glucokinase
regulatory protein, which also leads to nuclear sequestra-
tion of the enzyme (23).
Glucokinase serves a critical physiological function as
the -cell glucose sensor. It determines the glucose thresh-
old for insulin release because of the low afﬁnity of the
enzyme for its substrate, glucose (half-maximal activity,
S0.5, occurs at 7.5 mmol/l glucose). Heterozygous muta-
tions that reduce enzyme activity cause a subtype of
maturity-onset diabetes of the young 2 (MODY2), whereas,
as noted above, heterozygous activating mutations cause
hypoglycemia. Expression of these activating mutations
shows increased afﬁnity for glucose with elevations of
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glucose thresholds for insulin release (24).
Based on the initial cases reported, glucokinase hyper-
insulinism has been assumed to be a mild form of hypo-
glycemia that can easily be managed medically. However,
one reported case with a more severe clinical phenotype
of uncontrollable hypoglycemia suggests that the range
of manifestations of glucokinase hyperinsulinism may
be greater than has been appreciated (14). The purpose
of this report is to describe three children with hyper-
insulinism caused by de novo glucokinase mutations
who exhibit marked differences in responsiveness to
medical therapy that correlate with differences in en-
zyme activity indexes.
RESEARCH DESIGN AND METHODS
All clinical studies were approved by the institutional review board of the
Children’s Hospital of Philadelphia. Patient tests were performed in the
Clinical Translational Research Center of the Children’s Hospital of Philadel-
phia. Protein sensitivity and acute insulin response tests to calcium, leucine,
and glucose were carried out as previously described (25,26). Insulin assays
were performed using an enzyme-linked immunosorbent assay kit (Mercodia;
Alpco Diagnostics, Salem, NH).
Identiﬁcation of glucokinase gene mutations. Genomic DNA from periph-
eral lymphocytes was ampliﬁed by PCR using published primer sequences for
glucokinase (Genbank accession no. M88011) (27). Products were se-
quenced using a BigDye terminator cycle sequencing kit (Applied Biosys-
tems, Foster City, CA) and analyzed using Sequencher 3.1 (Gene Codes,
Ann Arbor, MI).
Biochemical characterization of ins454A, W99L, and M197I mutants.
Recombinant human islet wild-type glucokinase, the three patient mutants
(ins454A, W99L, and ins454A), known instability mutant E300K, and a series of
designed mutations (M197A, D, E, F, K, L, T, and V) were generated using
methods previously described (28). Brieﬂy, the mutations were cloned for
expression as glucokinase fusion proteins containing a COOH-terminal
glutathionyl S-transferase (GST). GST-glucokinase was produced in Esch-
erichia coli and then puriﬁed from crude extracts to near homogeneity by
afﬁnity chromatography using glutathione-agarose (Sigma, St. Louis, MO).
Characterization of GST cleaved enzymes was also performed by cleavage
of GST with Factor Xa. The product was then puriﬁed again using
glutathione-agarose and Factor Xa with benzamidine Sepharose 6B to yield
the cleaved proteins.
Kinetic analysis of the expressed forms of glucokinase was performed
using the protocols developed previously (13,16), both in the presence and
absence of the glucokinase activator compound RO0281675. The activity
index, an expression of the proposed enzyme’s in situ phosphorylation
capacity, and the theoretical threshold for glucose-stimulated insulin release
were calculated as previously described (13,20). Kinetic analysis was also
performed in the presence of recombinant human glucokinase regulatory
protein, a competitive inhibitor of glucokinase, with and without sorbitol-6-
phosphate, a structural analog of fructose-6-phosphate that enhances glucoki-
nase regulatory protein inhibition (16). For this purpose the assay was
performed with glucose at 3 mmol/l for wild type and the glucose concentra-
tion adjusted based on S0.5 of the different mutants in both the presence and
the absence of 10 mol/l sorbitol-6-phosphate.
The stability of mutant and wild-type GST-glucokinase to low glucose and
high temperature was tested as previously described by spectrophotometric
enzyme assay (16,29). The stability of W99L was measured using tryptophan
ﬂuorescence by comparing the quantum (photonic) yield of wild-type glucoki-
nase to the mutant glucokinase protein solution (30).
Structural analysis. Structural modeling of M197I, W99L, ins454A, and
published activating mutations was performed using the structure of the
super-open form of glucokinase and closed form determined by Kamata et al.
(21). Modeling was performed using a SwissPdb viewer (31).
Patients. Child 1 is a 17-year-old male subject who had a large-for-gestational-
age birth weight of 4.8 kg at term. Hypoglycemia was detected in the ﬁrst hour
after delivery, and high rates of intravenous glucose infusion were required to
control blood glucose levels (18 mg  kg
1  min
1; normal 5–6). Plasma
insulin levels at times of hypoglycemia were found to be elevated (8–15
U/ml; normal 3). He was not fully responsive to diazoxide, deﬁned as being
able to fast 12 h with blood glucose of 70 mg/dl. However, treatment with
a high dose of diazoxide (20 mg  kg
1  day
1) and feedings every 4 h
prevented symptoms of hypoglycemia, although plasma glucose levels re-
mained largely between 2.8 and 3.3 mmol/l (50–60 mg/dl). There were no
family members with hypoglycemia.
At 1 year of age, he was referred to the Children’s Hospital of Philadelphia
because of persistently low plasma glucose values of 2.2–3.3 mmol/l (40–60
mg/dl). A trial of octreotide gave only transient improvement in control of
hypoglycemia (32). Because of persistent hypoglycemia at 23 months of age,
a 95% pancreatectomy was performed; however, this failed to control hypo-
glycemia. Diazoxide treatment was retried, but plasma glucose fell to 3.3
mmol/l (60 mg/dl) after only5ho ffasting. Treatment consisted of feedings
given frequently, day and night. Despite the low levels of plasma glucose,
hypoglycemic symptoms rarely occurred, mainly triggered by exercise or
high-carbohydrate feedings. His parents report that his hypoglycemia ap-
peared to improve after age 11 years, and nighttime feedings were stopped.
However, they also report that he now has occasional hyperglycemia after
meals, suggestive of mild glucose intolerance. Currently, child 1 has normal
school performance.
Child 2 is a boy with a normal term birth weight of 3.2 kg. Hypoglycemia
was not recognized until age 6 years, when he became unarousable a few
hours after eating and was found to have a blood glucose of 48 mg/dl (2.7
mmol/l). There was no family history of hypoglycemia. Treatment with 10 mg 
kg
1  day
1 of diazoxide failed to control hypoglycemia. He was suspected to
have an insulinoma because of the apparent new onset of hypoglycemia.
Endoscopic ultrasound suggested a lesion in the head of the pancreas that
was found to be a lymph node at surgery; biopsies of the neck and body of
the pancreas were normal. Octreotide failed to control hypoglycemia.
Successful control of hypoglycemia has required a combination of diazox-
ide (15 mg  kg
1  day
1) plus a low rate of continuous dextrose overnight
by gastrostomy tube (2 mg  kg
1  min
1). School performance was
considered to be normal.
Child 3 is a 16-year-old boy with a large-for-date birth weight of 4.9 kg at 41
weeks of gestation. Hypoglycemia was detected in the ﬁrst hours after birth,
requiring treatment with intravenous dextrose at 12 mg  kg
1  min
1. There
was no history of hypoglycemia in the parents or in two older siblings.
Hyperinsulinemic hypoglycemia was documented but was considered to
have resolved after 2 months of treatment with prednisone. There was no
further suspicion of hypoglycemia until 14 years of age, when he suffered
two brief seizures, each occurring 3 h after breakfast. Plasma glucose was
found to be 2.2 mmol/l (40 mg/dl). Hyperinsulinemic hypoglycemia was di-
agnosed. A high dose of diazoxide at 900 mg (15 mg  kg
1  day
1) was
required to maintain fasting plasma glucose levels 3.9 mmol/l (70 mg/dl).
School performance was considered normal, although not on a par with his
siblings.
RESULTS
Figure 1 shows the diurnal proﬁle of plasma glucose levels
in child 1 and child 3 (at ages 4 and 15 years, respectively).
Glucose values ranged between narrow limits, rarely rising
into the normal range even after meals, but also rarely
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FIG. 1. Diurnal patterns of plasma glucose concentrations in child 1
and child 3. Plasma glucose was measured before meals and after
overnight fasting conditions. Shaded area indicates the normal range
of plasma glucose (4.0–5.0 mmol/l, 72–90 mg/dl). Child 1 was 4 years
old, 2 years after near-total pancreatectomy; child 3 was 15 years old.
Neither child was on medical therapy. Mean glucose was 50  2 mg/dl in
child 1 and 63  1 mg/dl in child 3. P < 0.0001 between children.
GLUCOKINASE HYPERINSULINISM
1420 DIABETES, VOL. 58, JUNE 2009falling very low, even during 12 h of overnight fasting
(child 3). Child 1, whose hypoglycemia was more difﬁcult
to manage, had signiﬁcantly lower mean plasma glucose
levels (mean  SE) than child 3 (50  2 vs. 63  1 mg/dl,
respectively; P  0.0001). As shown in Fig. 2, child 2 fasted
for 24 h with a stable plasma glucose ranging from 3 to 4
mmol/l (54–72 mg/dl) before dropping to 2.8 mmol/l (50
mg/dl). During the fast he developed a signiﬁcant ketone-
mic response, albeit lower than normally seen at this level
of blood glucose (-hydroxybutyrate 2.5 mmol/l).
Table 1 shows the responses in child 1 and child 3 to
stimulation tests of insulin secretion. Both children showed
exaggerated acute insulin responses to intravenous glucose.
In child 3, acute insulin responses to calcium and leucine
were normal, in contrast to the hyperresponsiveness to
calcium and leucine seen in patients with KATP channel or
glutamate dehydrogenase mutations, respectively. In further
contrast to patients with KATP or glutamate dehydrogenase
hyperinsulinism, hypoglycemia was not provoked by oral
protein tolerance tests in either child 1 or child 3. All three
children had normal serum concentrations of cholesterol and
triglyceride.
Review of the surgical specimen of resected pancreas
from child 1 showed normal islet distribution, shape, and
size from head to tail. There were occasional large endo-
crine cell nuclei that occupied an area at least three times
as large as the surrounding endocrine cell nuclei, similar
to the histological features seen in recessive KATP hyper-
insulinism. The surgical biopsies from child 2 showed
normal pancreas.
Genetic mutation analysis. In child 1, mutation analysis
of genomic DNA identiﬁed a heterozygous novel missense
mutation, ins454A (nt 13631-364 ins CGG). In child 2, a
glucokinase mutation was suspected because of the sta-
bility of his hypoglycemia (Fig. 2); he was found to have a
heterozygous novel W99L missense mutation (nt 296
GT). In child 3, a mutation in glucokinase was also
suspected because of the stability of hypoglycemia; he had
a heterozygous novel M197I mutation (nt 591 GT). The
mutations were not detected in any of the children’s
parents and were not found in 100 normal chromosomes.
No mutations were found in other hyperinsulinism genes,
including ABCC8, KCNJ11, and GLUD1.
Biochemical analysis of expressed ins454A, W99L,
and M197I glucokinase mutations. Table 2 shows the
enzymatic activities of the puriﬁed mutant forms of glu-
cokinase. The ins454A mutation resulted in a markedly
increased afﬁnity for glucose (decreased glucose S0.5). The
glucose S0.5 values in child 2 and child 3 were reduced to
a lesser degree. The turnover rate, kcat, of the ins454A
mutation was similar to wild-type glucokinase; however,
kcat for the GST-glucokinase fusion M197I mutant was
	60% of wild type, and kcat for W99L was increased
compared with wild type. Hill numbers for all three
mutations were only slightly reduced compared with wild
type. Kinetic variables for the GST-glucokinase fusion
proteins were similar to their cleaved counterparts
(data not shown). For all mutations, the calculated
enzyme activity index was increased compared with
wild type, consistent with a gain of glucokinase enzyme
function. This was especially true for child 1, whose
ins454A mutation resulted in an activity index 25
times normal, consistent with his poorer response to
diazoxide therapy compared with child 2 and child 3.
Because enzyme stability can potentially affect glucoki-
nase activity, we examined the effect of incubating
ins454A and M197I mutant enzymes under conditions of
low glucose and high temperature (Fig. 3A and B). The
stability of enzyme activity of the two mutants after
incubation at low glucose concentrations was similar to
that of wild-type glucokinase and was much greater than
that of the known diabetes-associated instability mutant
E300K (Fig. 3A). The thermal stability of the ins454A and
M197I mutant proteins was intermediate between that of
wild-type and E300K glucokinase (Fig. 3B). The thermal
stability of W99L was investigated by tryptophan ﬂuores-
cence under similar glucose conditions (30) and was also
intermediate between that of wild type and the E300K
instability mutant (data not shown).
As shown in Table 2, the ins454A GST-glucokinase
mutant was unresponsive to the glucokinase activator
compound RO0281675, suggesting that its activity was
already maximal. The response of the W99L and M197I
GST-glucokinase mutants to the activator was similar to
wild type. The latter ﬁnding may be attributable to the
M197I mutation being 19 Å away from the activator site
and therefore unlikely to interfere with activator bind-
ing. Another plausible explanation is the moderate
degree of enzyme activation leaving room for further
activation by the glucokinase activator, as in the case of
W99L.
Figure 3C and D shows the response of two of the
mutant glucokinase enzymes to inhibition by hepatic glu-
cokinase regulatory protein. W99L and M197I GST-glu-
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FIG. 2. Plasma glucose and -hydroxybutyrate responses to fasting in
child 2. Mean plasma glucose was 64  1 mg/dl. -Hydroxybutyrate
values increased from 0.1 to 1.8 mmol/l, whereas fasting plasma glucose
levels decreased. At the end of the fast, plasma C-peptide was sup-
pressed (0.16 nmol/l, normal 0.26–1.32 nmol/l). Glucose response to
glucagon stimulation was 36 mg/dl. Reference normals when fasting
blood glucose <50 mg/dl: -hydroxybutyrate >2.5 mmol/l, and glycemic
response to glucagon >30 mg/dl. ‚, plasma glucose (SureStep bedside
meter); Œ, -hydroxybutyrate (Precision Xtra bedside meter).
TABLE 1
Acute insulin response to insulin secretagogues and plasma lipid
concentrations
Child 1 Child 2 Child 3 Normal
Glucose AIR (pmol/l) 483 — 474 318  228
Calcium AIR (pmol/l) — — 24.0 0.6  11.4
Leucine AIR (pmol/l) — — 30.0 12.0  66
Cholesterol (mmol/l) 2.9 4.3 4.3 2.8–5.8
Triglycerides (mmol/l) 0.29 0.61 1.7 0.4–1.9
Reference normal values for acute insulin response tests are from
Ferry et al. (25) and Grimberg et al. (26). AIR, acute insulin response.
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regulatory protein as wild type (W99L results not shown).
The ins454A mutant showed little response to inhibition by
glucokinase regulatory protein.
Biochemical analysis of additional mutants at residue
197. As shown in Table 2, to evaluate the function of the
M197 residue, eight additional mutations were designed
that substituted a range of amino acids from hydrophobic
TABLE 2
Kinetic characteristics of glucokinase ins454A, W99L, and M197I
Mutants
Yield
(mg/l)
kcat
(sec
1)
Glucose S0.5
(mmol/l)
ATP Km
(mmol/l)
nH
(Hill number) Activity index
Activation by
GKA (fold)
EC50 for GKA
(mol/l)
ins454A 10.9  3.1 53.2  2.9 1.1  0.1 0.3 1.2 39.5  1.7 No activation N/A
W99L 19.9  1.7 85.6  3.1 2.9  0.1 0.4 1.6 13.3  0.8 11.8 4.3
M197I 62.1  0.3 38.1  4.5 2.6  0.2 1.5 1.6 4.8  0.3 11.9 4.9
M197L 34.5 54.5 5.4 1.0 1.4 3.8 13.9 6.2
M197V 25.1 44.7 2.6 0.5 1.7 8.0 13.1 3.5
M197A 36.4 53.3 3.2 0.3 1.7 7.0 14.7 3.8
M197T 26.7 53.9 4.1 0.5 1.6 4.4 18.3 5.5
M197F 40.3 21.2 54.6 0.2 1.3 0.1 8.6 6.1
M197K 36.4 3.78 86.7 0.2 1.1 0.03 13.6 9.3
M197D 27.7 10.3 197.0 0.3 1.1 0.03 6.0 2.8
M197E 6.82 21.0 56.2 1.3 0.2 0.1 9.0 2.7
Wild type 43.4  3.8 62.3  4.8 7.6  0.2 0.4 1.7 1.5  0.1 15.8  0.6 6.9  0.4
Kinetic data of puriﬁed expressed GST-tagged glucokinase with hyperinsulinism-causing ins454A (child 1), W99L (child 2), and M197I (child
3) mutations. EC50 relates to the activity index. GKA, glucokinase activator; EC50, half-maximal effective concentration.
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FIG. 3. Thermal stability of GST-tagged wild-type and mutant glucokinase (A and B). Response of GST-glucokinase mutants to inhibition with
glucokinase regulatory protein (GKRP) (C and D). GST-glucokinase levels were 22 nmol/l in all tests. A: Effect of glucose concentration on expressed
GST-tagged glucokinase with ins454A and M197I hyperinsulinism mutations and the known E300K instability mutant. For M197I, the studies were not
extended below the glucose S0.5 of 2.6 mmol/l. B: Effect of temperature on mutant glucokinase enzyme activities. For these assays, enzymes were
incubated for 30 min with glucose levels at their respective S0.5. C and D: Inhibition of glucokinase activity by glucokinase regulatory protein measured
in the presence and absence of sorbitol-6-phosphate (S6P), respectively. E, ins454A; , M197I; , E300K; X, wild type.
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phobic residues for the normal methionine resulted in
increased afﬁnity for glucose and increased enzyme activ-
ity indexes, whereas changes to hydrophilic or amphi-
pathic residues reduced enzyme activity.
DISCUSSION
The results of these studies demonstrate that congenital
hyperinsulinism in these three children was caused by
three novel activating mutations of glucokinase, ins454A,
W99L, and M197I. Expression of the mutations demon-
strated changes in glucokinase kinetics consistent with
increased enzyme activity. Increases in calculated glucoki-
nase activity indexes ranged from 25 times normal in child
1, with the ins454A mutation, to three times normal in
child 3, with the M197I change. These differences in
enzyme activation correlated with the more severe diazox-
ide-unresponsive hypoglycemia of child 1; the intermedi-
ate, partially diazoxide-responsive hypoglycemia of child
2; and the milder diazoxide-responsive hypoglycemia of
child 3.
As shown in Fig. 4A, the mutations at positions 99, 197,
and 454 of glucokinase are located on the reverse side of
the enzyme, opposite the catalytic cleft. The ins454A
mutation is adjacent to three previously reported glucoki-
nase activating mutations (V455M, A456V, and V452L),
whereas the W99L mutation is located at the same position
as a previously reported W99R activating mutation (Table
3 summarizes known glucokinase hyperinsulinism muta-
tions). Most of the 11 glucokinase activating mutations
that have been identiﬁed occur in or close to the region of
the enzyme that interacts with allosteric activator com-
pounds, such as RO0281675, and with the inhibitory glu-
cokinase regulatory protein. Heredia et al. (33,34) have
shown that some of these mutations (T65I and A456V)
increase glucose binding to the enzyme, whereas the
others (W99R, Y214C, and V455M) facilitate enzyme
isomerization into the active form. The two mutations that
enhance glucose binding also abrogate interaction with
glucokinase regulatory protein, suggesting that these mu-
tations cause increased glucokinase activity by favoring
maintenance of the closed, active form of the enzyme and
preventing opening of the catalytic cleft into the inactive
form of the enzyme. The ins454A glucokinase mutation in
child 1 appears to ﬁt into this category of mutations, which
makes the enzyme unresponsive to both inhibition by
glucokinase regulatory protein and allosteric activation by
RO0281675. Loss of inhibition by glucokinase regulatory
protein does not seem to be a major determinant of
clinical phenotype (34) because the Y214C mutation re-
tains sensitivity to glucokinase regulatory protein but was
reported to have diazoxide-unresponsive hypoglycemia
similar to ins454A (Table 3).
The novel M197I amino acid substitution reported here
has a unique location that is remote from the other
glucokinase activating mutations. As shown in Fig. 4B and
C, the M197I mutation alters a methionine residue that
moves in and out of a hydrophobic pocket during the
transition between the active and inactive forms of glu-
cokinase. The importance of this hydrophobic lock-and-
key interaction is demonstrated by the series of designed
mutations of M197 (Table 2). Substitutions with isoleucine
or other hydrophobic amino acids retained or enhanced
glucokinase activity. However, substitutions with hydro-
philic amino acids essentially inactivated the enzyme.
These observations have been conﬁrmed in a recent report
by Pal and Miller (35). The M197I mutation indicates that
activating mutations of glucokinase need not be restricted
to the allosteric domain, where all previous defects have
been located, and suggests that additional mutation sites
are likely to be identiﬁed in patients with glucokinase
hyperinsulinism.
Glucokinase mutations have been found infrequently in
mutation analysis of patients with congenital hyperinsu-
linism, accounting for only 5 of 167 patients in recently
reported series (18) and only 3 of 212 cases we have
analyzed. Table 3 summarizes the major features of hyper-
insulinism caused by previously reported activating muta-
tions of glucokinase and the three additional mutations
described in this report. Familial cases account for 76% of
the 29 known patients. This contrasts with the high
proportion of de novo cases in glutamate dehydrogenase
hyperinsulinism and other dominant disorders, suggesting
that many cases are not identiﬁed in the absence of a
family history of hypoglycemia. Only 3 of the 29 patients
had surgery, suggesting a relatively mild hypoglycemia
phenotype, especially in the familial cases. Many of the
familial cases escaped recognition of their hypoglycemia
disorder until beyond the neonatal period or even into
adult life. In all of the familial cases, treatment with the
-cell KATP channel agonist diazoxide was reported to
have been successful in controlling hypoglycemia. Child 3
(M197I mutation) ﬁts this milder, diazoxide-responsive
phenotype, although it should be noted that unusually high
doses of diazoxide were needed to maintain even low-
normal levels of plasma glucose. However, similar to child
2 (W99L), incomplete responsiveness to diazoxide was
also apparent in some of the reported cases in the six
families with the mild hypoglycemia phenotype (W99R,
A456V).
In contrast, children with Y214C and ins454A mutations
had a much more severe form of hypoglycemia. Our child
1 with the ins454A mutations could not be controlled on
diazoxide, even at a very high dose of 20 mg  kg
1  day
1.
In the case of the Y214C mutation, diazoxide responsive-
ness is unknown because only a low dose was tried. Both
of these children required surgery and continued to have
poorly controlled hypoglycemia, despite near-total pancre-
atectomy. These cases make it apparent that the clinical
manifestations of hyperinsulinism in some glucokinase
mutations can be as severe and as unresponsive to diazox-
ide treatment as in children with hyperinsulinism caused
by recessive mutations of the KATP channel subunits
sulfonylurea receptor 1 and Kir6.2.
The observations in the present three cases identify
clinical features that may be useful for distinguishing
glucokinase hyperinsulinism. A notable feature in the
cases presented here was the remarkable stability of their
hypoglycemia (Figs. 1 and 2), consistent with a resetting of
the threshold for insulin release at a value lower than
normal. This contrasts with other forms of hyperinsulin-
ism in infants, where blood glucose concentrations can fall
without interruption to extremely low values. Insulin
responses to secretagogues may also help to distinguish
glucokinase hyperinsulinism from other disorders. The
glucokinase activating mutations in our three cases are not
associated with hyperresponsiveness to calcium (as seen
in KATP hyperinsulinism) or leucine (as seen in glutamate
dehydrogenase hyperinsulinism), did not predispose to
protein-induced hypoglycemia (as seen in KATP and gluta-
mate dehydrogenase hyperinsulinism), but are accompa-
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is blunted in KATP hyperinsulinism).
Information about islet morphologic abnormalities in
patients with glucokinase hyperinsulinism remains lim-
ited. In child 1, a small proportion of islet cells showed
nucleomegaly similar to, but to a lesser extent than, that
seen in diffuse KATP hyperinsulinism. The increase in
islet size described by Cuesta-Munoz et al. (14) in a child
with a Y214C glucokinase mutation was not apparent in
our child. No abnormalities were noted in the pancreas
of the mother of the child with the T65I mutation (16).
Although further study may identify speciﬁc histological
features, current information suggests that it may not
be easy to distinguish glucokinase hyperinsulinism
from KATP hyperinsulinism or, possibly, from normal
pancreas.
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activating mutations on predicted glucose threshold for
insulin release, based on the relative activity indexes of
the expressed proteins in vitro. Cases reported to be
diazoxide unresponsive (ins454A and Y214C) have very
low glucose thresholds, as does the A456V mutation,
TABLE 3
Comparison of clinical and biochemical features of published glucokinase activating mutants associated with hyperinsulinism
V455M A456V T65I W99R Y214C G68V S64Y V452L ins454A W99L M197I
Number of families 1 2 1 1 — 1 —————
de novo case subjects — — — 1 1 — 1 1 1 1 1
Total cases (n  2 9 ) 5 5 2 3 1 8 111 11
Birth weight (kg) 2.9–4.1 2.4–3.8 3.1 3.1, 4.0 4.4 1.9–3.7 4.3 5.9 4.9 3.2 4.9
Age at diagnosis
Neonatal (n  8 ) — 1 1 2 1 — 111— —
Childhood (n  7 ) 21— — —3———1 —
Adolescence (n  4 ) 1— — — —2————1
Adulthood (n  1 0 ) 231 1 —3—————
Severity of hypoglycemia
Mild or untreated (n  1 2 ) 13— 1 —7—————
Diazoxide treated (n  13) 4 2 1 2 — — 1 1 — 1 1
Diazoxide and octreotide
treated (n  1 ) — — — — —1—————
Required surgery (n  3) — — 1 — 1 — — — 1 — —
Pretreatment plasma glucose
(normal  3.9 mmol/l) 1.3–2.5 2.1–3.5 2.2–3.0 2.0–3.5, 2.1 0.1–2.6 1.6–3.3 2.0 2.6–3.3 1.7–2.8 2.6–3.7 2.6–3.6
Response to diazoxide Yes Yes Yes Yes No Yes Yes Yes No Partial Yes
S0.5 (normal  7.55 mmol/l)* 3.0 2.0 1.8 4.5 1.2 1.9 1.5 2.6 1.1 2.9 2.6
Relative activity index* 5.2 17 3.1 4.1 130 16 22 11 26 8.9 3.1
Original clinical report
reference no. 12 13 14 15 16 17 18 19 — — —
*Values from published reports.
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FIG. 5. Calculated thresholds for glucose-stimulated insulin release (GSIR) in activating and inactivating mutations of glucokinase. Thresholds
are plotted against the inverse of the mutant enzyme activity index relative to wild-type (WT) enzyme. Because relative expression of the
glucokinase forms is affected by enzyme afﬁnity for glucose and the ambient glucose concentration, the wild-type enzyme dominates the estimated
threshold for the heterozygous inactivating defects, but the mutant enzyme dominates the threshold for activating mutations. Thus, the threshold
for inactivating mutations plateaus at 	7 mmol/l, whereas the calculated threshold for severe activating mutations approaches zero as the
relative activity increases. For purposes of consistency, all kinetic data in the ﬁgure are from the laboratory of F.M.M. Threshold and activity
indexes were calculated per Gloyn et al. (24). F, glucokinase hyperinsulinism mutations; E, MODY2 mutations; X, wild type. GK, glucokinase.
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diazoxide. In contrast, the better responses to diazoxide in
child 2 and child 3 correlate with higher calculated glucose
thresholds. It should be noted that the range of plasma
glucose levels in our three patients and in the reports of
other glucokinase hyperinsulinism cases (Table 3) tends to
be higher than their predicted glucose thresholds (Fig. 5).
This may partly reﬂect the effects of counterregulatory
responses to hypoglycemia. An additional potential prob-
lem in correlating data on glucokinase kinetics with clin-
ical features in patients is that some of the changes in
enzyme properties exert opposing effects. One example of
this phenomenon is the V62M mutation, which has been
associated with MODY2 diabetes (36). When expressed in
vitro, this mutation has an increased activity index consis-
tent with causing hypoglycemia, rather than diabetes. The
increased instability of this mutant form of glucokinase
may counterbalance its enhanced activity and explain why
the mutation results in a net loss of function in vivo (36).
Similarly, although the ins454A, W99L, and M197I muta-
tions have increased activity indexes, they also have
slightly reduced stability. Moreover, the impact of the
reduced afﬁnity of M197I for ATP in vivo is uncertain.
Given these problems, efforts to understand the in vivo and in
vitro phenotypes of glucokinase hyperinsulinism mutations
will require that accurate data be obtained on the clinical
features of affected individuals. For example, these data
should especially include careful documentation of the abil-
ity of diazoxide treatment to completely normalize plasma
glucose levels and accurate estimates of the in vivo glucose
“set point,” as illustrated in Figs. 1 and 2.
In summary, these three cases of congenital hyperinsu-
linism caused by activating mutations of glucokinase
emphasize the key role that this enzyme plays in setting
the glucose threshold of the pancreatic islets. These
children had de novo mutations, which made them difﬁcult
to recognize. Clues to their diagnosis included persistent,
but stable, hypoglycemia and exaggerated insulin re-
sponses to intravenous glucose stimulation. These cases
indicate that the spectrum of hyperinsulinism attributable
to glucokinase activating mutations can range from mild
and intermediate cases, which can be managed medically
with diazoxide, to severe cases that are diazoxide
unresponsive and may require additional treatment,
including near-total pancreatectomy, to control hypogly-
cemia. These cases also illustrate the potentials and limi-
tations of new approaches to develop glucokinase
activator drugs for the treatment of type 2 diabetes.
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